Covid-19 roundup: As­traZeneca paus­es vac­cine tri­al for chil­dren as blood clot probe con­tin­ues; EMA to in­ves­ti­gate ...

5 years ago
Coronavirus

David David­son’s R&D odyssey takes him out of blue­bird to an­oth­er biotech start­up with big plans to trans­form ...

5 years ago
People

Icosavax keeps up the ex­cite­ment for its VLP 'soc­cer balls,' earn­ing the RA Cap­i­tal stamp of ap­proval in $100M Se­ries ...

5 years ago
Financing
Coronavirus

FDA push­es eczema de­ci­sion for Eli Lil­ly's Olu­mi­ant, Pfiz­er's abroc­i­tinib back 3 months — rais­ing more ques­tions ...

5 years ago
Pharma
FDA+

No­var­tis taps DNA dam­age spe­cial­ist Ar­tios in $1.3B dis­cov­ery deal to com­ple­ment grow­ing ra­di­oli­gand port­fo­lio

5 years ago
Deals
Discovery

Fi­bro­Gen shares take a beat­ing as CEO re­veals safe­ty da­ta ma­nip­u­la­tion for its block­buster con­tender rox­adu­s­tat

5 years ago
R&D
FDA+

Near­ly 70% of Akcea's work­force is on the chop­ping block as Io­n­is ex­e­cutes ma­jor re­struc­tur­ing

5 years ago
People

Can em­ploy­ers man­date Covid-19 vac­cines un­der emer­gency au­tho­riza­tions? It’s com­pli­cat­ed

5 years ago
FDA+
Coronavirus

Catal­ent pledges to in­crease pro­duc­tion of Mod­er­na vac­cine at its In­di­ana fill-fin­ish plant

5 years ago
Deals
Manufacturing

In 1-2 punch, Mol­e­c­u­lar Tem­plates cuts first-gen can­di­date and los­es a Big Phar­ma part­ner; Charles Riv­er teams up ...

5 years ago
News Briefing

As­traZeneca’s big ADC part­ner pledges to pour $13.6B in­to can­cer R&D over next 5 years — and En­her­tu looms large

5 years ago
Pharma

Covid-19 roundup: EMA of­fi­cial says 'clear' link be­tween As­traZeneca shot and blood clots — re­port; No­vavax al­lows ...

5 years ago
Coronavirus

Af­ter No­var­tis walks on last STING drug, Chi­nook spits out or­phan Aduro as­sets

5 years ago
Deals

Min­eralys emerges with a new take on an old idea for the treat­ment of hy­per­ten­sion and $40M to play with

5 years ago
Financing

De­spite remde­sivir ap­proval and 2 big buy­outs, Gilead CEO Dan O'­Day sees pay fall 35% from 2019

5 years ago
People
Pharma

As Covid-19 vac­cine was be­ing de­vel­oped, Mod­er­na shelled out more than $1M for top ex­ec­u­tives' se­cu­ri­ty

5 years ago
People
Pharma

The 20(+1) un­der 40: In­side the next gen­er­a­tion of biotech lead­ers

5 years ago
Special

Eu­ro­pean Com­mis­sion preps for ma­jor over­haul of phar­ma leg­is­la­tion

5 years ago
Pharma
FDA+

With fresh in­vestor cash in hand, Volas­tra part­ners with Mi­crosoft to de­vel­op metasta­t­ic can­cer bio­mark­er plat­form

5 years ago
Financing
Deals

Big Phar­ma R&D vet­er­an with block­buster cre­den­tials re­turns to his biotech roots as Prothena's new CMO

5 years ago
People

MHRA kicks off new ac­cel­er­at­ed drug ap­proval path­way with ‘in­no­va­tion pass­ports’

5 years ago
Pharma
FDA+

With one pan­dem­ic still rag­ing, J&J bets $780M on a po­ten­tial flu ther­a­py for the next

5 years ago
Deals

Covid-19 roundup: FDA up­dates Mod­er­na vac­cine dose per vial counts; Vir's an­ti­body shows promise against vari­ants

5 years ago
Coronavirus

2,400 peo­ple re­main with­out rare dis­ease drug as Take­da man­u­fac­tur­ing woes con­tin­ue

5 years ago
Pharma
Manufacturing
First page Previous page 721722723724725726727 Next page Last page
A service from the Financial Times